In:
European Neurology, S. Karger AG, Vol. 81, No. 3-4 ( 2019), p. 163-166
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 Evidence is scarce regarding the safety of alteplase for acute stroke in patients with an active malignancy. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 We reviewed medical records for patients with both conditions treated at our institution over a 2-year period. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Five patients were identified, of which only one developed an asymptomatic intracerebral haemorrhage, and no systemic bleedings occurred. Functional outcomes and stroke severity, as measured by National Institutes of Health Stroke Scale and modified Rankin Scale, were favourable upon discharge. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 In the absence of active bleeding or known malignancy of the central nervous system, intravenous alteplase seems a reasonable option for patients with an active cancer and acute stroke.
Type of Medium:
Online Resource
ISSN:
0014-3022
,
1421-9913
Language:
English
Publisher:
S. Karger AG
Publication Date:
2019
detail.hit.zdb_id:
1482237-4
Permalink